Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 1.00 |
| ▸ | HPGD | P15428 | 11/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.86 |
| ▸ | MEN1 | O00255 | 4/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.79 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6534282 | 0.91 | HPGD (1.00) | ALDH1A1HPGDKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL6688057 | 0.90 | HPGD (1.00) | ALDH1A1HPGDKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL15233668 | 0.88 | ALDH1A1 (0.78) | ALDH1A1HPGDKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL31237652 | 0.87 | ALDH1A1 (0.82) | ALDH1A1HPGDKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL6534639 | 0.86 | HPGD (1.00) | ALDH1A1HPGDKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL29411859 | 0.86 | HPGD (1.00) | ALDH1A1HPGDKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL25910937 | 0.85 | ALDH1A1 (0.73) | ALDH1A1HPGDKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL31552893 | 0.85 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL2799908 | 0.83 | HPGD (0.76) | ALDH1A1HPGDKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL13232473 | 0.82 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4ESMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542239-B1 | USE OF ISOQUINOLONES FOR PREPARING DRUGS, NOVEL ISOQUINOLONES AND METHOD FOR SYNTHESISING SAME | Université Joseph Fourier (FR) | 2015-11-11 | — | — | EP | disclosed |
| US-8883763-B2 | Use of isoquinolones for preparing drugs, novel isoquinolones and method for synthesising same | UNIVERSITE JOSEPH FOURIER (FR) | 2014-11-11 | — | — | US | disclosed |
| US-20130096083-A1 | USE OF ISOQUINOLONES FOR PREPARING DRUGS, NOVEL ISOQUINOLONES AND METHOD FOR SYNTHESISING SAME | UNIVERSITE JOSEPH FOURIER (FR) | 2013-04-18 | — | — | US | disclosed |
| EP-2542239-A1 | USE OF ISOQUINOLONES FOR PREPARING DRUGS, NOVEL ISOQUINOLONES AND METHOD FOR SYNTHESISING SAME | Université Joseph Fourier (FR) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011107709-A1 | USE OF ISOQUINOLONES FOR PREPARING DRUGS, NOVEL ISOQUINOLONES AND METHOD FOR SYNTHESISING SAME | UNIVERSITE JOSEPH FOURIER (FR) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096083-A1 | USE OF ISOQUINOLONES FOR PREPARING DRUGS, NOVEL ISOQUINOLONES AND METHOD FOR SYNTHESISING SAME | GNAQ, HCCS, SDHA | ALDH1A1 2507/4885HPGD 61/4885KDM4E 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.